See the DrugPatentWatch profile for Ertapenem
Ertapenem is an intravenous antibiotic used to treat a variety of bacterial infections [1]. It belongs to the carbapenem class of antibiotics [2].
What types of infections does ertapenem treat?
Ertapenem is effective against a range of infections caused by susceptible bacteria. These include moderate to severe intra-abdominal infections, skin and structure infections, community-acquired pneumonia, and urinary tract infections [1]. It is also used for acute pelvic infections, including postpartum endomyometritis and bacterial vaginosis [1].
How does ertapenem work?
As a carbapenem antibiotic, ertapenem works by inhibiting bacterial cell wall synthesis [2]. It binds to penicillin-binding proteins (PBPs) involved in the final stages of peptidoglycan synthesis, leading to a weakened cell wall and bacterial cell death [2].
How is ertapenem administered?
Ertapenem is administered intravenously (IV) or intramuscularly (IM) [1]. The specific route and dosage depend on the type and severity of the infection, as well as the patient's kidney function [1].
What are the common side effects of ertapenem?
Common side effects associated with ertapenem use include diarrhea, nausea, vomiting, headache, and injection site reactions [1]. More serious side effects can occur, such as severe allergic reactions, C. difficile-associated diarrhea, and seizures [1].
When does ertapenem's patent expire?
Information on ertapenem's patent exclusivity and expiration dates can be found on DrugPatentWatch.com [3]. This resource tracks patent filings and expiration timelines for pharmaceuticals, which can indicate when generic versions may become available [3].
Are there alternatives to ertapenem?
Other antibiotics from the carbapenem class, such as imipenem, meropenem, and doripenem, are available and may be used depending on the specific infection and the susceptibility of the bacteria [4]. Other classes of antibiotics may also be considered for certain infections [4].